• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, July 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Gut Microbiota Modulates EHMT2 to Fight Kidney Cancer

Bioengineer by Bioengineer
March 5, 2026
in Cancer
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In a groundbreaking study published on March 5, 2026, researchers have unveiled an unprecedented link between the gut microbiota and renal cell carcinoma (RCC), one of the most prevalent and lethal forms of kidney cancer. This novel research, led by Lee et al., demonstrates that the probiotic strain Lacticaseibacillus rhamnosus Fb7-311 can modulate the epigenetic regulator EHMT2

Tags: EHMT2 modulation by probioticsEHMT2 role in cancer progressionepigenetic regulation in renal cell carcinomaepigenetic targets in kidney cancergut microbiome influence on epigeneticsgut microbiota and kidney cancergut-kidney axis in cancer therapyLacticaseibacillus rhamnosus Fb7-311 effectsmicrobiota-driven cancer modulationprobiotic strains in oncologyprobiotic treatment for RCCrenal cell carcinoma novel therapies

Share12Tweet8Share2ShareShareShare2

Related Posts

Survival Outcomes Linked to Timing of Immune Checkpoint Inhibitor Dosing

July 19, 2026

Randomized Phase II Trial Tests Nivolumab Then Nivolumab-Ipilimumab or Docetaxel

July 18, 2026

KPNA2 overexpression worsens T4 colorectal cancer prognosis by nuclear c-Myc suppression of p21

July 17, 2026

Blood DNA test better selects patients for prostate cancer radiopharmaceutical therapy

July 17, 2026

POPULAR NEWS

  • Groundbreaking Discovery: New Shark Species Identified for the First Time — Technology and Engineering

    Groundbreaking Discovery: New Shark Species Identified for the First Time

    34 shares
    Share 14 Tweet 9
  • Controlled Study Defines Pediatric Long COVID Features

    32 shares
    Share 13 Tweet 8
  • Behavioral Nudge Boosts Medication Prescriptions for Alcohol Reduction

    35 shares
    Share 14 Tweet 9
  • Clean Cooking and Remittances Slash Somalia’s Ecological Footprints

    31 shares
    Share 12 Tweet 8

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Sleep Quality Links Synergistically with Frailty to Increase Cardiometabolic Multimorbidity in Elderly Chinese

Cognitive reserve helps older adults resist frailty and recover better

Physical Activity and Health Inequality in China’s Older Adults

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.